Nasonex nasal spray

Nasonex Nasal Spray (mometasone furoate monohydrate) is a prescription corticosteroid spray designed for the management of nasal symptoms associated with allergic rhinitis in adults and pediatric patients. It works locally in the nasal passages to reduce inflammation, providing significant relief from congestion, sneezing, and runny nose. Clinically proven and widely recommended by healthcare professionals, it offers a targeted approach to seasonal and perennial allergy management with a favorable safety profile.

Features

• Active ingredient: mometasone furoate monohydrate (50 mcg per spray)
• Delivery system: metered-dose, manual pump spray bottle
• Preservative-free formulation after initial priming
• Suitable for use in patients aged 2 years and older
• Once-daily dosing regimen for maintenance therapy

Benefits

• Reduces nasal inflammation at the source, minimizing systemic exposure
• Provides 24-hour relief from allergic rhinitis symptoms with a single daily dose
• Improves overall quality of life by enabling normal breathing and reducing nasal irritation
• Non-sedating formula allows for use during daytime activities without drowsiness
• Prevents recurrence of nasal polyps after surgical removal in approved cases
• Suitable for long-term management under medical supervision

Common use

Nasonex Nasal Spray is commonly prescribed for the treatment of seasonal and perennial allergic rhinitis symptoms, including nasal congestion, rhinorrhea, sneezing, and pruritus. It is also indicated for the prophylaxis of seasonal allergic rhinitis symptoms when initiated 2–4 weeks prior to the anticipated start of the pollen season. Additionally, it is used as an adjunctive treatment for nasal polyps, reducing their size and associated symptoms such as impaired smell and obstruction.

Dosage and direction

For allergic rhinitis in adults and adolescents 12 years and older: 2 sprays in each nostril once daily (total dose 200 mcg). Once symptoms are controlled, reduction to 1 spray per nostril may be effective for maintenance. For children 2–11 years: 1 spray in each nostril once daily (total dose 100 mcg). For nasal polyps: 2 sprays in each nostril twice daily (total dose 400 mcg). Shake well before use. Prime the pump before first use or if not used for 14 days or more by releasing 10 sprays until a fine mist appears. Blow nose gently before use. Insert tip into nostril, pointing away from septum, and breathe in gently while spraying.

Precautions

Avoid use in patients with recent nasal septal ulcers, nasal surgery, or nasal trauma until healed. Monitor patients for development of nasal or pharyngeal fungal infections. Use with caution in patients with tuberculosis, untreated fungal, bacterial, or viral systemic infections, or ocular herpes simplex. Glaucoma or cataracts may occur with prolonged use; periodic intraocular pressure checks are advisable. Adrenal suppression may occur with very high doses or concomitant systemic corticosteroids. Not for ophthalmic use.

Contraindications

Hypersensitivity to mometasone furoate or any component of the formulation. Contraindicated in untreated localized infections involving the nasal mucosa. Avoid use in patients with active or quiescent tuberculosis infections of the respiratory tract.

Possible side effects

Common side effects (≥1%) include headache, pharyngitis, epistaxis, nasal irritation or burning, and cough. Less frequently reported effects include upper respiratory tract infection, dysgeusia, nausea, and dry nose. Rare but serious side effects may include nasal septal perforation, impaired wound healing, growth suppression in children, vision changes (glaucoma, cataracts), and signs of systemic corticosteroid effects with excessive doses.

Drug interaction

Although low systemic absorption limits interactions, caution is advised with strong CYP3A4 inhibitors (e.g., ketoconazole) which may increase mometasone exposure. Concurrent use with other corticosteroids (oral, inhaled, or intranasal) may increase the risk of hypothalamic-pituitary-adrenal axis suppression. No clinically significant interactions identified with commonly co-administered allergy medications such as antihistamines or decongestants.

Missed dose

If a dose is missed, administer as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed one. Resume the regular dosing schedule with the next administration.

Overdose

Acute overdose is unlikely due to low systemic bioavailability. Single doses up to 20 times the recommended dose have been administered without adverse effects. Chronic overdose may lead to symptoms of hypercorticism (e.g., moon face, central obesity, hypertension). Treatment should be supportive and symptomatic; consider discontinuation or dose reduction under medical supervision.

Storage

Store at room temperature (15–30°C or 59–86°F). Do not freeze. Keep the bottle upright and protected from light. Discard 120 days after opening, even if not entirely used. Keep out of reach of children and pets. Do not puncture or incinerate the container.

Disclaimer

This information is for educational purposes and does not replace professional medical advice. Always consult a healthcare provider for diagnosis and individualized treatment recommendations. Use only as prescribed. Do not discontinue or adjust dosage without consulting your physician.

Reviews

Clinical studies demonstrate that Nasonex Nasal Spray significantly improves nasal symptom scores compared to placebo, with onset of action within 12 hours for some symptoms and maximal effect within 1–2 weeks. Patient-reported outcomes indicate high satisfaction with symptom control, particularly regarding nasal congestion relief. Long-term studies (up to 12 months) support its safety and efficacy for perennial allergic rhinitis management. Healthcare providers frequently note its favorable tolerability and minimal impact on growth velocity in pediatric populations when used at recommended doses.